International Journal of Gynecological Cancer

Mucinous ovarian cancer
pp. 209-214(6)
Authors: HARRISON,; JAMESON,; GORE,

Influences on multidisciplinary team decision-making
pp. 215-222(8)
Authors: LANCELEY,; SAVAGE,; MENON,; JACOBS,

Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m² in patients with recurrent ovarian and peritoneal cancer
pp. 223-227(5)
Authors: YILDIRIM,; GULTEKIN,; AVCI,; INAL,; YUNUS,; TINAR,

Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer
pp. 228-234(7)
Authors: VERBORG,; CAMPBELL,; HIGHLEY,; RANKIN,

The role of frozen section evaluation in the diagnosis of adnexal mass
pp. 235-240(6)
Authors: TASKIRAN,; ERDEM,; ONAN,; BOZKURT,; YAMAN-TUNC,; ATAOGLU,; GUNER,

P53 and bcl-2 assessment in serous ovarian carcinoma
pp. 241-248(8)
Authors: PALMER,; SANT CASSIA,; IRWIN,; MORRIS,; ROLLASON,

A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum
pp. 249-254(6)
Authors: BROWN,; RETTENMAIER,; LOPEZ,; GRAHAM,; MICHA,; GOLDSTEIN,

Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis
pp. 255-261(7)
Authors: SMITH,; MACDONALD,; LEE,; GAFFNEY,

Extent of extracranial disease is a powerful predictor of survival in patients with brain metastases from gynecological cancer
pp. 262-268(7)
Authors: GROWDON,; LOPEZ-VARELA,; LITTELL,; OLIVA,; SEIDEN,; KRASNER,; LEE,; FULLER,

The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology
pp. 269-273(5)
Authors: CHI,; BARAKAT,; PALAYEKAR,; LEVINE,; SONODA,; ALEKTIAR,; BROWN,; ABU-RUSTUM,

A cost comparison of two strategies for treating stage IB2 cervical cancer
pp. 274-278(5)
Authors: LACHANCE,; DARUS,; STUKENBORG,; SCHNEIDER,; RICE,; JAZAERI,

Does a “one-stop” gynecology screening clinic for women in hereditary nonpolyposis colorectal cancer families have an impact on their psychological morbidity and perception of health?
pp. 279-284(6)
Authors: WOOD,; MUNOT,; SHERIDAN,; DUFFY,

Human papillomavirus DNA integration and messenger RNA transcription in cervical low- and high-risk squamous intraepithelial lesions in Austrian women
pp. 285-294(10)
Authors: MANAVI,; HUDELIST,; FINK-RETTER,; GSCHWANTLER-KAULICH,; PISCHINGER,; CZERWENKA,

Distribution and clinical significance of human papillomavirus subtypes in Shenzhen city, People's Republic of China
pp. 295-299(5)
Authors: DAI,; HUANG,; TANG,; LV,; LI,; YIN,

Increased expression of Toll-like receptor 5 during progression of cervical neoplasia
pp. 300-305(6)
Authors: KIM,; LEE,; CHOI,; SONG,; BAE,

Clinical utility of liquid-based cytology for the characterization and management of endometrial polyps in postmenopausal age
pp. 306-311(6)
Authors: FAMBRINI,; BUCCOLIERO,; BARGELLI,; CIONI,; PICIOCCHI,; PIERALLI,; ANDERSSON,; SCARSELLI,; TADDEI,; MARCHIONNI,

LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking
pp. 312-317(6)
Authors: LINDSTRÖM,; EKMAN,; STENDAHL,; TOT,; HENRIKSSON,; HEDMAN,; HELLBERG,

Early identification of persistent trophoblastic disease with serum hCG concentration ratios
pp. 318-323(6)
Authors: vanTROMMEL,; NGOduc,; MASSUGER,; SCHIJF,; SWEEP,; THOMAS,

Prognostic factors in women 45 years of age or younger with endometrial cancer
pp. 324-328(5)
Authors: UHARČEK,; MLYNČEK,; RAVINGER,; MATEJKA,

Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model
pp. 329-338(10)
Authors: WU,; CELESTINO,; MILAM,; SCHMELER,; BROADDUS,; ELLENSON,; LU,

Characterization of a newly established uterine carcinosarcoma cell line featuring the sarcomatous phenotype of the tumor in vitro
pp. 339-344(6)
Authors: SCHULTEN,; WOLF-SALGÓ,; GRÜNDKER,; GUNAWAN,; FÜZESI,

Prognostic impact of body mass index and effect of overweight and obesity on surgical and adjuvant treatment in early-stage epithelial ovarian cancer
pp. 345-351(7)
Authors: SKÍRNISDÓTTIR,; SORBE,

The risk of developing uterine sarcoma after tamoxifen use
pp. 352-356(5)
Authors: LAVIE,; BARNETT-GRINESS,; NAROD,; RENNERT,

EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients
pp. 357-362(6)
Authors: LU,; YE,; SHEN,; FU,; CHEN,; WAN,; XIE,

Role of diaphragmatic surgery in 69 patients with ovarian carcinoma
pp. 363-368(6)
Authors: DEVOLDER,; AMANT,; NEVEN,; vanGORP,; LEUNEN,; VERGOTE,

Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma
pp. 369-372(4)
Authors: ARORA,; TEWARI,; COWAN,; SAFFARI,; MONK,; BURGER,

Cystic struma ovarii presenting as pseudo-Meigs' syndrome with elevated CA125 levels. A case report and review of the literature
pp. 372-375(4)
Authors: MITROU,; MANEK,; KEHOE,

Treatment of aggressive angiomyxoma with aromatase inhibitor prior to surgical resection
pp. 375-379(5)
Authors: GILES,; LIU,; LIDNER,; MAGTIBAY,

Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary
pp. 379-383(5)
Authors: JAISHUEN,; BERRIOS-RIVERA,; SIRISABYA,; ZHENG,; LI,; KAVANAGH,

Original film of the Okabayashi's radical hysterectomy by Okabayashi himself in 1932, and two films of the precise anatomy necessary for nerve-sparing Okabayashi's radical hysterectomy clarified by Shingo Fujii
pp. 383-385(3)
Author: FUJII,

To the Editor:
pp. 386-386(1)